Clinical Trial

UBT251 Injection Phase II Clinical Study (CKD)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese/overweight chronic kidney disease (CKD) population
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-20.
Status change: Active, Not Recruiting → Recruiting 2025-11-19
Trial Details
NCT Number NCT07134335
Lead Sponsor The United Bio-Technology (Hengqin) Co., Ltd.
Conditions Obesity & Overweight, Chronic Kidney Disease
Enrollment 180 participants
Start Date 2025-09-01
Primary Completion 2030-07-11 (estimated)
Study Completion 2030-07-11 (estimated)
Updated on ClinicalTrials.gov 2025-11-25